Antibody-Mediated Rejection

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 393-407

  Akalin, Enver ^a   Watschinger, Bruno ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti HLA antibody; humoral rejection; kidney transplantation; sensitization

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; GENZYME; HLA ANTIBODY; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD GROUP ABO SYSTEM; CLINICAL TRIAL; FIBROBLAST; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE EPITHELIUM; KIDNEY GRAFT REJECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANTIBODY FORMATION; BIOPSY; DISEASE PROGRESSION; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; SEVERITY OF ILLNESS INDEX;

EID: 34347273041     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.05.001     Document Type: Article

References (79)

1. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
2. Feucht H.E. Complement C4d in graft capillaries-the missing link in the recognition of humoral alloreactivity. Am J Transplant 3 (2003) 646-652
3. Bray R.A., Nickerson P.W., Kerman R.H., and Gebel H.M. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 29 (2004) 41-54
4. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 (2003) 665-673
5. Sumitran-Holgersson S., Wilczek H.E., Holgersson J., and Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2002) 268-277
6. Hankey K.G., Drachenberg C.B., Papadimitriou J.C., Klassen D.K., Philosophe B., Bartlett S.T., et al. MIC expression in renal and pancreatic allografts. Transplantation 73 (2002) 304-306
7. Mizutani K., Terasaki P., Rosen A., Esquenazi V., Miller J., Shih R.N., et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5 (2005) 2265-2272
8. Mizutani K., Terasaki P.I., Shih R.N., Pei R., Ozawa M., and Lee J. Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum Immunol 67 (2006) 223-229
9. Suarez-Alvarez B., Lopez-Vazquez A., Diaz-Molina B., Bernardo-Rodriguez M.J., Alvarez-Lopez R., Pascual D., et al. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection. Transplantation 82 (2006) 354-361
10. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365 (2005) 1570-1576
11. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352 (2005) 558-569
12. Rodriguez P.C., Arroyave I.H., Mejia G., and Garcia L.F. Detection of alloantibodies against non-HLA antigens in kidney transplantation by flow cytometry. Clin Transplant 14 (2000) 472-478
13. Ferry B.L., Welsh K.I., Dunn M.J., Law D., Proctor J., Chapel H., et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol 5 (1997) 17-24
14. Perrey C., Brenchley P.E., Johnson R.W., and Martin S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 6 (1998) 101-106
15. Joosten S.A., van Dixhoorn M.G., Borrias M.C., Benediktsson H., van Veelen P.A., van Kooten C., et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 160 (2002) 1301-1310
16. Joosten S.A., Sijpkens Y.W., van Ham V., Trouw L.A., van der Vlag J., van den Heuvel B., et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5 (2005) 383-393
17. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 71 (2001) 886-892
18. Morgun A., Shulzhenko N., Unterkircher C.S., Diniz R.V., Pereira A.B., Silva M.S., et al. Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 23 (2004) 204-209
19. Gebel H.M., Harris S.B., Zibari G., and Bray R.A. Conundrums with FlowPRA beads. Clin Transplant 16 Suppl 7 (2002) 24-29
20. Wahrmann M., Exner M., Haidbauer B., Schillinger M., Regele H., Kormoczi G., et al. [C4d]FlowPRA screening-a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 66 (2005) 526-534
21. Wahrmann M., Exner M., Schillinger M., Haidbauer B., Regele H., Kormoczi G.F., et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 6 (2006) 1033-1041
22. Feucht H.E., Schneeberger H., Hillebrand G., Burkhardt K., Weiss M., Riethmuller G., et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 43 (1993) 1333-1338
23. Racusen L.C., Halloran P.F., and Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 4 (2004) 1562-1566
24. Magil A.B., and Tinckam K.J. Focal peritubular capillary C4d deposition in acute rejection. Nephrol Dial Transplant 21 (2006) 1382-1388
25. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3 (2003) 708-714
26. Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., Williams W.W., Tolkoff-Rubin N., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 10 (1999) 2208-2214
27. Bohmig G.A., Regele H., Exner M., Derhartunian V., Kletzmayr J., Saemann M.D., et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 12 (2001) 2482-2489
28. Mauiyyedi S., Crespo M., Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 13 (2002) 779-787
29. Mauiyyedi S., Pelle P.D., Saidman S., Collins A.B., Pascual M., Tolkoff-Rubin N.E., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12 (2001) 574-582
30. Herzenberg A.M., Gill J.S., Djurdjev O., and Magil A.B. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 13 (2002) 234-241
31. Lederer S.R., Kluth-Pepper B., Schneeberger H., Albert E., Land W., and Feucht H.E. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 59 (2001) 334-341
32. Regele H., Exner M., Watschinger B., Wenter C., Wahrmann M., Osterreicher C., et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 16 (2001) 2058-2066
33. Mengel M., Bogers J., Bosmans J.L., Seron D., Moreso F., Carrera M., et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 5 (2005) 1050-1056
34. Fidler M.E., Gloor J.M., Lager D.J., Larson T.S., Griffin M.D., Textor S.C., et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 4 (2004) 101-107
35. Gloor J.M., Cosio F.G., Rea D.J., Wadei H.M., Winters J.L., Moore S.B., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6 (2006) 1841-1847
36. Haas M., Rahman M.H., Racusen L.C., Kraus E.S., Bagnasco S.M., Segev D.L., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 6 (2006) 1829-1840
37. Kato M., Morozumi K., Takeuchi O., Oikawa T., Koyama K., Usami T., et al. Complement fragment C4d deposition in peritubular capillaries in acute humoral rejection after ABO blood group-incompatible human kidney transplantation. Transplantation 75 (2003) 663-665
38. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., and Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 2 (1966) 662-665
39. Williams G.M., Hume D.M., Hudson Jr. R.P., Morris P.J., Kano K., and Milgrom F. "Hyperacute" renal-homograft rejection in man. N Engl J Med 279 (1968) 611-618
40. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., and Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49 (1990) 85-91
41. Halloran P.F., Schlaut J., Solez K., and Srinivasa N.S. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53 (1992) 550-555
42. Regele H., Bohmig G.A., Habicht A., Gollowitzer D., Schillinger M., Rockenschaub S., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 13 (2002) 2371-2380
43. Takemoto S.K., Zeevi A., Feng S., Colvin R.B., Jordan S., Kobashigawa J., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 (2004) 1033-1041
44. Al Aly Z., Yalamanchili P., Cortese C., Salinas-Madrigal L., and Bastani B. C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: an uncommon finding. Transpl Int 18 (2005) 800-805
45. Akalin E., Murphy B., Sehgal V., Schroppel B., de Boccardo G., Bromberg J.S., et al. Low prevalence of C4d positivity in chronic allograft nephropathy and transplant glomerulopathy biopsies [abstract]. J Am Soc Nephrol 17 (2006) 114A
46. Martin L., Guignier F., Mousson C., Rageot D., Justrabo E., and Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 76 (2003) 395-400
47. Akalin E., Dikman S., Murphy B., Bromberg J.S., and Hancock W.W. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 3 (2003) 1116-1120
48. Cascalho M., and Platt J.L. Basic mechanisms of humoral rejection. Pediatr Transplant 9 (2005) 9-16
49. Vongwiwatana A., Tasanarong A., Hidalgo L.G., and Halloran P.F. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 196 (2003) 197-218
50. Jin Y.P., Fishbein M.C., Said J.W., Jindra P.T., Rajalingam R., Rozengurt E., et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 65 (2004) 291-302
51. Jindra P.T., Zhang X., Mulder A., Claas F., Veale J., Jin Y.P., et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 82 (2006) S33-S35
52. Abraham K.A., Brown C., Conlon P.J., Donohoe J., Hickey D.P., O'Neill D., et al. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apheresis 18 (2003) 103-110
53. Hickstein H., Korten G., Bast R., Barz D., Templin R., Schneidewind J.M., et al. Protein A immunoadsorption (i.a.) in renal transplantation patients with vascular rejection. Transfus Sci 19 Suppl (1998) 53-57
54. Jordan S.C., Quartel A.W., Czer L.S., Admon D., Chen G., Fishbein M.C., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 (1998) 800-805
55. Koller H., Steurer W., Mark W., Margreiter R., Lhotta K., Mayer G., et al. Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: a report of three cases. Transpl Int 17 (2004) 177-181
56. Lehrich R.W., Rocha P.N., Reinsmoen N., Greenberg A., Butterly D.W., Howell D.N., et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol 66 (2005) 350-358
57. Min L., Shuming J., Zheng T., Daxi J., Huiping C., Zhihong L., et al. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transplant 19 (2005) 51-55
58. Montgomery R.A., Zachary A.A., Racusen L.C., Leffell M.S., King K.E., Burdick J., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887-895
59. Pascual M., Saidman S., Tolkoff-Rubin N., Williams W.W., Mauiyyedi S., Duan J.M., et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66 (1998) 1460-1464
60. Persson N.H., Bucin D., Ekberg H., Kallen R., Omnell Persson M., Simanaitis M., et al. Immunoadsorption in acute vascular rejection after renal transplantation. Transplant Proc 27 (1995) 3466
61. Pretagostini R., Berloco P., Poli L., Cinti P., Di Nicuolo A., De Simone P., et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J 42 (1996) M645-M648
62. Shah A., Nadasdy T., Arend L., Brennan J., Leong N., Coppage M., et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77 (2004) 1399-1405
63. White N.B., Greenstein S.M., Cantafio A.W., Schechner R., Glicklich D., McDonough P., et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 78 (2004) 772-774
64. Bohmig G.A., Wahrmann M., Regele H., Exner M., Robl B., and Druml W. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Eur Surg 38 Suppl 211 (2006) 25-26
65. Jordan S., Cunningham-Rundles C., and McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 3 (2003) 653-664
66. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15 (2004) 3256-3262
67. Jordan S.C., Vo A., Bunnapradist S., Toyoda M., Peng A., Puliyanda D., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
68. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
69. Rocha P.N., Butterly D.W., Greenberg A., Reddan D.N., Tuttle-Newhall J., Collins B.H., et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 (2003) 1490-1495
70. Jordan S.C., Vo A.A., Toyoda M., Tyan D., and Nast C.C. Post-transplant therapy with high-dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 9 (2005) 155-161
71. Akalin E., Ames S., Sehgal V., Fotino M., Daly L., Murphy B., et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 76 (2003) 1444-1447
72. Akalin E., Ames S., Sehgal V., Murphy B., Bromberg J.S., Fotino M., et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 79 (2005) 742
73. Akalin E., and Bromberg J.S. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 66 (2005) 359-363
74. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6 (2006) 859-866
75. Becker Y.T., Becker B.N., Pirsch J.D., and Sollinger H.W. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4 (2004) 996-1001
76. Akalin E., Sehgal V., Murphy B., Ames S., Bromberg J.S., Dikman S., et al. Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. Transplantation 79 (2005) 257-258
77. Karpinski M., Rush D., Jeffery J., Exner M., Regele H., Dancea S., et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12 (2001) 2807-2814
78. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3 (2003) 1488-1500
79. Akalin E., and Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 1 (2006) 433-440